Neurocovid : Pharmacological Recommendations for Delirium Associated With COVID-19
Copyright © 2020 Academy of Consultation-Liaison Psychiatry. Published by Elsevier Inc. All rights reserved..
BACKGROUND: The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as one of the biggest health threats of our generation. A significant portion of patients are presenting with delirium and neuropsychiatric sequelae of the disease. Unique examination findings and responses to treatment have been identified.
OBJECTIVE: In this article, we seek to provide pharmacologic and treatment recommendations specific to delirium in patients with COVID-19.
METHODS: We performed a literature search reviewing the neuropsychiatric complications and treatments in prior coronavirus epidemics including Middle Eastern respiratory syndrome and severe acute respiratory syndrome coronaviruses, as well as the emerging literature regarding COVID-19. We also convened a work group of consultation-liaison psychiatrists actively managing patients with COVID-19 in our hospital. Finally, we synthesized these findings to provide preliminary pharmacologic recommendations for treating delirium in these patients.
RESULTS: Delirium is frequently found in patients who test positive for COVID-19, even in the absence of respiratory symptoms. There appears to be a higher rate of agitation, myoclonus, abulia, and alogia. No data are currently available on the treatment of delirium in patients with COVID-19. Extrapolating from general delirium treatment, Middle Eastern respiratory syndrome/severe acute respiratory syndrome case reports, and our experience, preliminary recommendations for pharmacologic management have been assembled.
CONCLUSIONS: COVID-19 is associated with neuropsychiatric symptoms. Low-potency neuroleptics and alpha-2 adrenergic agents may be especially useful in this setting. Further research into the pathophysiology of COVID-19 will be key in developing more targeted treatment guidelines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Psychosomatics - 61(2020), 6 vom: 19. Nov., Seite 585-596 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Baller, Erica B [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.11.2020 Date Revised 10.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.psym.2020.05.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314022066 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314022066 | ||
| 003 | DE-627 | ||
| 005 | 20231225151831.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.psym.2020.05.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1046.xml |
| 035 | |a (DE-627)NLM314022066 | ||
| 035 | |a (NLM)32828569 | ||
| 035 | |a (PII)S0033-3182(20)30153-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Baller, Erica B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neurocovid |b Pharmacological Recommendations for Delirium Associated With COVID-19 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.11.2020 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Academy of Consultation-Liaison Psychiatry. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emerged as one of the biggest health threats of our generation. A significant portion of patients are presenting with delirium and neuropsychiatric sequelae of the disease. Unique examination findings and responses to treatment have been identified | ||
| 520 | |a OBJECTIVE: In this article, we seek to provide pharmacologic and treatment recommendations specific to delirium in patients with COVID-19 | ||
| 520 | |a METHODS: We performed a literature search reviewing the neuropsychiatric complications and treatments in prior coronavirus epidemics including Middle Eastern respiratory syndrome and severe acute respiratory syndrome coronaviruses, as well as the emerging literature regarding COVID-19. We also convened a work group of consultation-liaison psychiatrists actively managing patients with COVID-19 in our hospital. Finally, we synthesized these findings to provide preliminary pharmacologic recommendations for treating delirium in these patients | ||
| 520 | |a RESULTS: Delirium is frequently found in patients who test positive for COVID-19, even in the absence of respiratory symptoms. There appears to be a higher rate of agitation, myoclonus, abulia, and alogia. No data are currently available on the treatment of delirium in patients with COVID-19. Extrapolating from general delirium treatment, Middle Eastern respiratory syndrome/severe acute respiratory syndrome case reports, and our experience, preliminary recommendations for pharmacologic management have been assembled | ||
| 520 | |a CONCLUSIONS: COVID-19 is associated with neuropsychiatric symptoms. Low-potency neuroleptics and alpha-2 adrenergic agents may be especially useful in this setting. Further research into the pathophysiology of COVID-19 will be key in developing more targeted treatment guidelines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a consultation-liaison psychiatry | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a delirium | |
| 650 | 4 | |a neuropsychiatry | |
| 650 | 4 | |a psychopharmacology | |
| 650 | 7 | |a Adrenergic alpha-2 Receptor Agonists |2 NLM | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 650 | 7 | |a Central Nervous System Depressants |2 NLM | |
| 650 | 7 | |a Dopamine Agonists |2 NLM | |
| 650 | 7 | |a GABA Modulators |2 NLM | |
| 650 | 7 | |a Melatonin |2 NLM | |
| 650 | 7 | |a JL5DK93RCL |2 NLM | |
| 650 | 7 | |a Lorazepam |2 NLM | |
| 650 | 7 | |a O26FZP769L |2 NLM | |
| 700 | 1 | |a Hogan, Charlotte S |e verfasserin |4 aut | |
| 700 | 1 | |a Fusunyan, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Ivkovic, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Luccarelli, James W |e verfasserin |4 aut | |
| 700 | 1 | |a Madva, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Nisavic, Mladen |e verfasserin |4 aut | |
| 700 | 1 | |a Praschan, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Quijije, Nadia V |e verfasserin |4 aut | |
| 700 | 1 | |a Beach, Scott R |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Felicia A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Psychosomatics |d 1961 |g 61(2020), 6 vom: 19. Nov., Seite 585-596 |w (DE-627)NLM000063827 |x 1545-7206 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2020 |g number:6 |g day:19 |g month:11 |g pages:585-596 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.psym.2020.05.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2020 |e 6 |b 19 |c 11 |h 585-596 | ||